Fresenius SE & Co. KGaA (FSNUY) Income Statement Analysis

See more : Turmalina Metals Corp. (TBX.V) Income Statement Analysis – Financial Results

Complete financial analysis of Fresenius SE & Co. KGaA (FSNUY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresenius SE & Co. KGaA, a leading company in the Medical – Care Facilities industry within the Healthcare sector.

You may be interested

Telefónica, S.A. (TEF) Income Statement Analysis – Financial Results
Toho Gas Co., Ltd. (THOGF) Income Statement Analysis – Financial Results
PT Mark Dynamics Indonesia Tbk (MARK.JK) Income Statement Analysis – Financial Results
ASM International NV (ASMIY) Income Statement Analysis – Financial Results
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) Income Statement Analysis – Financial Results

Fresenius SE & Co. KGaA (FSNUY)

Industry: Medical - Care Facilities

Sector: Healthcare

Website: https://www.fresenius.com

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	22.30B	40.84B	37.52B	36.28B	35.41B	33.53B	33.89B	29.08B	27.63B	23.23B	20.33B	19.29B	16.52B	15.97B	14.16B	12.34B	11.36B	10.78B	7.89B	7.27B	7.06B	7.51B
Cost of Revenue	17.24B	30.12B	27.21B	25.96B	25.06B	23.70B	23.41B	19.96B	19.09B	16.39B	13.95B	13.00B	10.88B	10.65B	9.53B	8.41B	7.68B	7.35B	5.30B	4.90B	4.79B	5.07B
Gross Profit	5.06B	10.73B	10.31B	10.32B	10.35B	9.83B	10.48B	9.13B	8.53B	6.84B	6.38B	6.29B	5.64B	5.33B	4.64B	3.93B	3.68B	3.43B	2.59B	2.38B	2.28B	2.44B
Gross Profit Ratio	22.68%	26.26%	27.48%	28.44%	29.22%	29.33%	30.92%	31.39%	30.89%	29.45%	31.40%	32.60%	34.13%	33.35%	32.74%	31.84%	32.38%	31.79%	32.82%	32.68%	32.22%	32.45%
Research & Development	661.00M	867.00M	805.00M	751.00M	645.00M	673.00M	558.00M	500.00M	464.00M	369.00M	348.00M	305.00M	267.00M	244.00M	240.00M	479.00M	-184.00M	-167.00M	-149.00M	-133.00M	121.00M	138.00M
General & Administrative	2.41B	5.52B	4.39B	4.37B	4.39B	3.86B	4.59B	3.39B	3.28B	2.52B	2.24B	2.25B	2.81B	2.66B	2.34B	1.97B	1.89B	0.00	0.00	0.00	1.37B	1.46B
Selling & Marketing	750.00M	1.22B	1.06B	1.06B	1.02B	1.02B	948.00M	916.00M	471.00M	435.00M	414.00M	380.00M	341.00M	0.00	0.00	0.00	-467.00M	-433.00M	-402.00M	-220.00M	0.00	0.00
SG&A	3.16B	6.74B	5.45B	5.43B	5.41B	4.87B	5.54B	4.30B	3.75B	2.95B	2.66B	2.63B	2.81B	2.66B	2.34B	1.97B	-467.00M	-433.00M	-402.00M	-220.00M	1.37B	1.46B
Other Expenses	99.00M	-207.00M	-105.00M	-219.00M	-305.00M	-154.00M	-210.00M	0.00	444.00M	406.00M	387.00M	366.00M	-100.00M	-66.00M	-31.00M	68.00M	0.00	0.00	0.00	0.00	-522.00M	-609.00M
Operating Expenses	3.92B	7.40B	6.15B	5.96B	5.75B	5.39B	5.89B	4.80B	4.66B	3.73B	3.39B	3.31B	3.08B	2.91B	2.58B	2.45B	-651.00M	-600.00M	-551.00M	-353.00M	1.52B	1.63B
Cost & Expenses	21.16B	37.52B	33.36B	31.92B	30.81B	29.09B	29.30B	24.76B	23.75B	20.12B	17.34B	16.31B	13.96B	13.55B	12.11B	10.86B	7.03B	6.75B	4.75B	4.54B	6.31B	6.70B
Interest Income	114.00M	187.00M	124.00M	93.00M	162.00M	355.00M	197.00M	96.00M	255.00M	128.00M	50.00M	54.00M	56.00M	30.00M	22.00M	25.00M	27.00M	0.00	0.00	0.00	297.00M	345.00M
Interest Expense	530.00M	694.00M	630.00M	752.00M	881.00M	942.00M	848.00M	678.00M	868.00M	730.00M	634.00M	720.00M	587.00M	596.00M	602.00M	456.00M	395.00M	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.48B	1.16B	2.65B	2.71B	2.41B	1.50B	1.44B	1.22B	1.12B	937.00M	843.00M	776.00M	674.00M	639.00M	562.00M	783.00M	421.00M	399.00M	320.00M	315.00M	325.00M	341.00M
EBITDA	2.73B	3.10B	6.95B	7.19B	7.25B	6.23B	6.23B	5.61B	5.25B	4.18B	3.83B	3.89B	3.19B	3.02B	2.61B	2.35B	2.06B	4.43B	3.46B	3.04B	1.08B	1.15B
EBITDA Ratio	12.23%	15.87%	18.52%	19.74%	20.38%	18.57%	18.36%	19.24%	18.99%	17.99%	19.10%	20.15%	19.33%	18.91%	18.41%	19.07%	41.82%	41.06%	43.86%	41.86%	15.32%	15.33%
Operating Income	1.14B	3.51B	4.16B	4.39B	4.63B	5.25B	4.59B	4.33B	3.88B	3.11B	2.99B	2.98B	2.56B	2.42B	2.05B	1.48B	1.61B	1.44B	969.00M	845.00M	781.00M	837.00M
Operating Income Ratio	5.13%	8.59%	11.08%	12.09%	13.08%	15.66%	13.54%	14.88%	14.03%	13.40%	14.71%	15.46%	15.51%	15.14%	14.50%	11.97%	14.17%	13.40%	12.28%	11.62%	11.06%	11.15%
Total Other Income/Expenses	-428.00M	-215.00M	-506.00M	-659.00M	-719.00M	-587.00M	-667.00M	-582.00M	-613.00M	-602.00M	-584.00M	-592.00M	-631.00M	-632.00M	-611.00M	-363.00M	-368.00M	-1.44B	-969.00M	-845.00M	-249.00M	-291.00M
Income Before Tax	715.00M	2.81B	3.65B	3.73B	3.91B	4.66B	3.94B	3.75B	3.26B	2.51B	2.41B	2.39B	1.93B	1.79B	1.44B	1.11B	1.24B	0.00	0.00	0.00	532.00M	546.00M
Income Before Tax Ratio	3.21%	6.89%	9.73%	10.27%	11.05%	13.91%	11.62%	12.88%	11.81%	10.81%	11.84%	12.40%	11.69%	11.18%	10.19%	9.03%	10.93%	0.00%	0.00%	0.00%	7.53%	7.27%
Income Tax Expense	477.00M	697.00M	833.00M	903.00M	883.00M	950.00M	905.00M	1.05B	965.00M	700.00M	669.00M	659.00M	604.00M	581.00M	452.00M	440.00M	3.92B	3.70B	2.92B	2.56B	223.00M	202.00M
Net Income	-594.00M	2.12B	2.82B	2.82B	3.03B	2.03B	1.81B	1.56B	1.36B	1.07B	1.01B	926.00M	1.33B	1.21B	991.00M	270.00M	409.00M	329.00M	221.00M	167.00M	115.00M	134.00M
Net Income Ratio	-2.66%	5.18%	7.51%	7.78%	8.55%	6.05%	5.35%	5.36%	4.92%	4.59%	4.97%	4.80%	8.04%	7.54%	7.00%	2.19%	3.60%	3.05%	2.80%	2.30%	1.63%	1.79%
EPS	0.37	3.77	5.05	5.06	5.44	0.91	0.82	0.71	0.62	0.49	0.47	0.45	0.68	0.62	0.51	0.14	0.22	0.18	0.15	0.34	0.23	0.27
EPS Diluted	0.63	3.77	5.05	5.06	5.43	0.91	0.81	0.71	0.62	0.49	0.47	0.44	0.67	0.62	0.51	0.13	0.22	0.18	0.15	0.34	0.23	0.27
Weighted Avg Shares Out	947.77M	561.26M	558.06M	557.45M	556.82M	2.23B	2.22B	2.19B	2.18B	2.17B	2.15B	2.08B	1.96B	1.94B	1.94B	1.90B	1.86B	1.84B	503.49M	492.54M	492.54M	492.54M
Weighted Avg Shares Out (Dil)	563.24M	561.26M	558.16M	557.74M	557.42M	2.23B	2.23B	2.20B	2.20B	2.18B	2.16B	2.10B	1.98B	1.96B	1.94B	1.91B	1.88B	1.86B	507.40M	494.03M	493.32M	492.54M

Fresenius: Maximum Pessimism Reached, Potential Triple-Digit 3-Year Rate Of Return

December 3, 2022seekingalpha.com

I've been buying Fresenius in small portions and adding to my position again and again over the past year. It's now more than 3% of my portfolio. While this company remains a long-term turnaround play, there are plenty of such...

Fresenius SE: A Buy After Quarterly Results

November 1, 2022seekingalpha.com

Fresenius SE is reporting mediocre results once again with Fresenius Medical Care struggling due to labor shortage and macroeconomic challenges. While Fresenius Medical Care and Fresenius Kabi are struggling, Fresenius Helios is improving again after two challenging years due to...

Fresenius SE & Co. KGaA (FSNUF) Q3 2022 Earnings Call Transcript

October 31, 2022seekingalpha.com

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael Sen – Chief Executive Officer Sara Hennicken – Chief Financial Officer Conference Call...

Fresenius - No One Likes A Contrarian During A Downturn

September 25, 2022seekingalpha.com

I've received plenty of inquiries with regards to Fresenius and its somewhat terrible performance YTD so far. Readers are asking if I'm "out" the company, or if I continue to believe that this company can turn around at any point...

Fresenius SE CEO to quit after earnings outlook sours

August 19, 2022reuters.com

FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit following the COVID pandemic and a surge in costs.

Fresenius: Too Cheap, Measured By Sum-Of-The-Parts

August 18, 2022seekingalpha.com

The shares of Fresenius, one of the world's largest healthcare groups, have been in a downward and then a sideways trend since 2017. Corona pandemic has been a major challenge, especially for its subsidiary Fresenius Medical Care. Despite further waves...

Fresenius SE & Co. KGaA (FSNUF) CEO Stephan Sturm on Q2 2022 Results - Earnings Call Transcript

August 3, 2022seekingalpha.com

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Stephan Sturm - President and Chief Executive Officer Rachel Empey - Chief...

Fresenius: Revisiting The Thesis - Still A Buy

June 19, 2022seekingalpha.com

We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wondering whether it's still investable.

Fresenius SE & Co. KGaA (FSNUF) CEO Stephan Sturm on Q1 2022 Results - Earnings Call Transcript

May 4, 2022seekingalpha.com

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q1 2022 Earnings Conference Call May 4, 2022 7:30 AM ET Company Participants Stephan Sturm – President & Chief Executive Officer Rachel Empey – Chief Financial Officer Markus Georgi – Head of Investor Relations...